# Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients

> **NCT04696939** · PHASE2 · UNKNOWN · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 100 (estimated)

## Conditions studied

- Small-cell Lung Cancer
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT04696939
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01
- **Primary completion:** 2022-08
- **Final completion:** 2023-10
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04696939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04696939, "Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04696939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*